Is it safe to use antidepressants after a stroke?

Expert Opinion on Drug Safety

Volumn 4, Issue 5, 2005, Pages 885-897

  Rampello, Liborio ^a   Battaglia, Giuseppe ^b   Raffaele, Rocco ^a   Vecchio, Ignazio ^a   Alvano, Alessandro ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Antidepressant; Depression; Stroke

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LISURIDE; MAPROTILINE; METHYLPHENIDATE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

AKATHISIA; ANOREXIA; BODY WEIGHT DISORDER; BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; MICTURITION DISORDER; NAUSEA; NERVOUSNESS; NEUROPATHY; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PYRIDOXINE DEFICIENCY; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STROKE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; RISK FACTORS; SAFETY; SEROTONIN UPTAKE INHIBITORS;

EID: 24344444940     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.5.885     Document Type: Review

References (127)

1. ANDERSEN G, VESTERGAARD K, INGEMANN-NIELSEN M, LAURITZEN L: Risk factors for post-stroke depression. Acta Psychiatr. Scand. (1995) 92(3):193-198.
2. ANDERSEN G, VESTERGAARD K, LAURITZEN L: Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke (1994) 25(6):1099-1104.
3. WIART L, PETIT H, JOSEPH PA, MAZAUX JM, BARAT M: Fluoxetine in Early Poststroke Depression. A Double-Blind Placebo-Controlled Study. Stroke (2000) 31:1829.
4. LYKETSOS CG, TREISMAN GJ, LIPSEY JR, MORRIS PL, ROBINSON RG: Does stroke cause depression? J. Neuropsychiatry Clin. Neurosci. (1998) 10(1):103-107.
5. ROBINSON RG: Neuropsychiatric consequences of stroke. Ann. Rev. Med. (1997) 48:217-229.
6. ROBINSON RG, MORRIS PLP, FEDOROFF P: Depression and cerebrovascular disease. J. Clin. Psychiatry (1990) 51:26-31.
7. JOLOBE OM: Depression and its relation to lesion location after stroke. J. Neurol. Neurosurg. Psychiatry (1998) 65(3):410.
8. CARSON AJ, MACHALE S, ALLEN K et al.: Depression after stroke and lesion location: a systematic review. Lancet (2000) 8(9224):122-126.
9. CHARATAN FB, FISK A: Mental and emotional results of strokes. N.Y. State J. Med. (1978) 78:1403-1405.
10. THE SUNNYBROOK STROKE STUDY: Functional and Neuroanatomic Correlations in Poststroke Depression. Stroke (2000) 31:637.
11. GAINOTTI G, AZZONI A, GASPARINI F, MARRA C, RAZZANO C: Relation of lesion location o verbal and non verbal mood measures in stroke patients. Stroke (1997) 28:2145-2149.
12. GAINOTTI G, ANTONUCCI G, MARRA C, PAOLUCCI S: Relation between depression after stroke, antidepressant therapy, and functional recovery. J. Neurol. Neurosurg. Psychiatry (2001) 71(2):258-261.
13. KAUHANEN M, KORPELAINEN JT, HILTUNEN P et al.: Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke (1999) 30:1875-1880.
14. FRUHWALD S, LOEFFLER H, EHER R, SALETU B, BAUMHACKL U: The relationship between depression, anxiety and quality of life - a study of stroke patients compared to chronic low back pain and myocardial ischemia patients. Psychopathology (2001) 34:50-56.
15. KING RB: Quality of life after stroke. Stroke (1996) 27:1467-1472.
16. SUENKELER ICH, NOWAK M, MISSELWITZ B et al.: Timecourse of healthrelated quality of life as determined 3, 6 and 12 months after stroke - relationship to neurological deficit, disability and depression. J. Neurol. (2002) 249:1160-1167.
17. KOTILA M, NUMMINEN H, WALTIMO O, KASTE M: Depression after stroke: results of the Finnstroke Study. Stroke (1998) 29:368-372.
18. LAURITZEN L, BENDSEN BB, VILMAR T, BENDSEN EB, LUNDE M, BECH P: Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. Psychopharmacology (1994) 114:119-122.
19. LIPSEY JR, ROBINSON R G, PEARLSON GD, RAO K, PRICE TR: Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet (1984) 11:297-300.
20. VASWANI M, LINDA FK, RAMESH S: Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry. (2003) 27(1):85-102.
21. SKOP BP, BROWN TM: Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics (1996) 37:12-16.
22. DE ABAJO FJ, GARCÍA RODRÍGUEZ LA, MONTERO D: Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ (1999) 319:1106-1109.
23. VAN WALRAVEN C, MAMDANI MM, WELLS PS, WILLIAMS JI: Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ (2001) 323:1-6.
24. LAZARUS LW, MOBERG PJ, LANGSLEY PR, LINGAM VR: Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch. Phys. Med. Rehabil. (1994) 75(4):403-406.
25. JOHNSON ML, ROBERTS MD, ROSS AR, WITTEN CM: Methylphenidate in stroke patients with depression. Am. J. Phys. Med. Rehabil. (1992) 71(4):239-241.
26. SHIMA S: The efficacy of antidepressants in post-stroke depression. Keio J. Med. (1997) 46 (1):25-26.
27. GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, ET AL: Drug interactions with newer antidepressants: role of human cytochromes P450. J. Clin. Psychiatry (1998) 59(15):19-?.
28. KIMURA M, ROBINSON RG, KOSIER JT: Treatment of cognitive impairment after post-stroke depression: a double-blind treatment trial. Stroke (2000) 31(7):1482-1486.
29. ANDERSEN G, VESTERGAARD K, RIIS JO: Citalopram for post-stroke pathological crying. Lancet (1993) 2 342(8875):837-839.
30. ANDERSEN G: Treatment of uncontrolled crying after stroke. Drugs Aging (1995a) 6(2):105-111.
31. ANDERSEN G, VESTERGAARD K, LAURITZEN LU: Effective treatment of depression following apoplexy with citalopram. Ugeskr. Laeger (1995b) 3 157(14):2000-2003.
32. RIGLER SK: Management of poststroke depression in older people. Clin. Geriatr. Med. (1999) 15(4):765-783.
33. STAMENKOVIC M, SCHINDLER S, KASPER S: Therapy of post-stroke depression with fluoxetine. A pilot project. Nervenarzt. (1996) 67(1):62-67.
34. DAM M, TONIN P, DE BONI A et al.: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke (1996) 27:1211-1214.
35. PAOLUCCI S, ANTONUCCI G, GRASSO MG et al.: Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc. Dis. (2001) 12(3):264-271.
36. CHEER SM, GOA KL: Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs (2001) 61(1):81-110.
37. GOODNICK PJ, HERNANDEZ M: Treatment of depression in comorbid medical illness. Expert. Opin. Pharmacother. (2000) 1(7):1367-1384.
38. SOLAI LK, MULSANT BH, POLLOCK BG: Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging (2001) 18(5):355-368.
39. BOURIN M: Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum. Psychopharmacol. (2003) 18(3):185-190.
40. COLE MG, ELIE LM, MCCUSKER J, BELLAVANCE F, MANSOUR A: Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review. J. Geriatr. Psychiatry Neurol. (2001) 14(1):37-41.
41. GUPTA A, PANSARI K, SHETTY H: Post-stroke depression. Int. J. Clin. Pract. (2002) 56(7):531-537.
42. KATAYAMA Y, USUDA K, NISHIYAMA Y, KATSURA K: Post-stroke depression. Nippon Ronen Igakkai Zasshi. (2003) 40(2):127-129.
43. FRUEHWALD S, GATTERBAUER E, REHAK P, BAUMHACKL U: Early fluoxetine treatment of post-stroke depression. A three-month double-blind placebo-controlled study with an open-label long-term follow up. J. Neurol. (2003) 250:347-351.
44. SPALLETTA G, CALTAGIRONE C: Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. Funct. Neurol. (2003) 18(4):227-232.
45. TURNER-STOKES L, HASSAN N: Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: treatment alternatives. Clin. Rehabil. (2002) 16(3):248-260.
46. VAN DE MEENT H, GEURTS AC, VAN LIMBEEK J: Pharmacologic treatment of poststroke depression: a systematic review of the literature. Top. Stroke Rehabil. (2003) 10(1):79-92.
47. PERETTI S, JUDGE R, HINDMARCH I: Safety and tolerability considerations: tricyclic antidepressants versus selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. (2000) 403:17-25.
48. HERRMANN N: Use of SSRIs in the elderly: obvious benefits but unappreciated risks. Can. J. Clin. Pharmacol. (2000) 7(2):91-95.
49. BRYMER C, WINOGRAD C: Fluoxetine in elderly patients: is there a cause for concern? J. Am. Geriatr. (1992) 40:902-905.
50. ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry (1994) 151:1735-1739.
51. GOLDSTEIN DJ, HAMILTON SH, MASICA DN, BEASLEY CM: Fluoxetine in medically stable, depressed geriatric patients: effects on weight. J. Clin. Psychopharmacol. (1997) 17:365-369.
52. ROBINSON RG, SCHULTZ SK, CASTILLO C et al.: Nortriptyline Versus Fluoxetine in the Treatment of Depression and in Short-Term Recovery After Stroke: A Placebo-Controlled, Double-Blind Study. Am. J. Psychiatry (2000) 157:351-359.
53. FRANCO K, MALHOTRA S: Poststroke Depression. Am. J. Psychiatry (2001) 158:658-659.
54. SUSSMAN N, GINSBERG DL: Weight gain associated with SSRIs: a paradox? Primary Psychiatry (1998) 5:28-39.
55. WILSON K, MOTTRAM P: A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int. J. Geriatr. Psychiatry (2004) 19(8):754-762.
56. RAMPELLO L, CHIECHIO S, NICOLETTI G et al.: Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl.) (2004) 173(1-2):73-78.
57. RAMPELLO L, NICOLETTI G, RAFFAELE R, DRAGO F: Comparative effects of Amitriptyline and Amineptine in patients affected by anxious depression. Neuropsycobiology (1995) 31:130-134.
58. RAMPELLO L, NICOLETTI G, RAFFAELE R: Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr. Scand. (1991) 84:552-554.
59. RAMPELLO L, NICOLETTI F, NICOLETTI F: Dopamine and depression. Therapeutic implications. CNS Drugs (2000) 13(1):35-45.
60. RAMPELLO L, ALVANO A, CHIECHIO S, RAFFAELE R, VECCHIO I, MALAGUARNERA M: An evaluation of efficacy and safety of reboxetine in elderly patients affected by 'retarded' post-stroke depression A random, placebo-controlled study. Arch. Gerontol. Geriatr. (2005) 40(3):275-285.
61. DAHMEN N, MARX J, HOPF HC, TETTENBORN B, RÖDER R: Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke (1999) 30:691-692.
62. THASE ME: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry (1998) 59:502-508.
63. KIMURA M, KANETANI K, IMAI R, SUZUKI H, ISAYAMA K, ENDO S: Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int. Clin. Psychopharmacol. (2002) 17(3):121-125.
64. GEKHT AB, SOROKINA IB, BOGOLEPOVA AN, GUDKOVA AA: Experience with ixel (milnacipran hydrochloride) use in the treatment of patients with post-stroke depression. Ter. Arkh. (2003) 75(10):34-38.
65. REDING MJ, ORTO LA, WINTER SW, FORTUNA IM, DI PONTE P, MCDOWELL FH: Antidepressant therapy after stroke: a double-blind trial. Arch. Neurol. (1986) 43:763-765.
66. DARKO W, GUHAROY R, ROSE F, LEHMAN D, PAPPAS V: Myoclonus secondary to the concurrent use of trazodone and fluoxetine. Vet. Hum. Toxicol. (2001) 43(4):214-215.
67. McCUE R and JOSEPH M: Venlafaxine- and trazodone-induced serotonin syndrome. Am. J. Psychiatry (2001) 158:2088-2089.
68. PRAPOTNIK M, WASCHGLER R, KONIG P, MOLL W, CONCA A: Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int. J. Clin. Pharmacol. Ther. (2004) 42(2):120-124.
69. SMALL NL and GIAMONNA KA: Interaction between warfarin and trazodone. Ann. Pharmacother. (2000) 34(6):734-736.
70. HOUGAKU H, MATSUMOTO M, HATA R et al.: Therapeutic effect of lisuride maleate on post-stroke depression. Nippon Ronen Igakkai Zasshi (1994) 31(1):52-59.
71. GEORGOTAS A, MCCUE RE, HAPWORTH W, FRIEDMAN E, KIM OM, WELKOWITZ J et al.: Comparative efficacy and safety of MAOI versus TCA's in treating depression in the elderly. Biol. Psychiatry (1986) 21:1155-66.
72. GEORGOTAS A, MCCUE RE, FRIEDMAN E et al.: A placebo-controlled comparison of nortripryline and phenelzine on orthostatic hypotension in elderly depressed patients. J. Clin. Psychopharmacol. (1987) 7:413-416.
73. LAZARUS LW, GROVES L, GIERL B, PANDEY G, JAVAID I, LESSER J et al.: Efficacy of phenelzine in geriatric depression. Biol. Psychiatry (1986) 21:699-701.
74. TOURIGNY-RIVARD MF. Pharmacotherapy of affective disorders in old age. Can. J. Psychiatry (1997) 42(1):10S-18S.
75. KATO M, IWATA H, KATAYAMA T, ASAI H, NARITA H, ENDO T: Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression. Biol. Pharm. Bull. (1997) 20(4):349-353.
76. KUBIN A, WIERRANI F, BURNER U, ALTH G, GRUNBERGER W: Hypericin-the facts about a controversial agent. Curr. Pharm. Des. (2005) 11(2):233-253.
77. BRENNER R, AZBEL V, MADHUSOODANAN S, PAWLOWSKA M: Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin. Ther. (2000) 22(4):411-419.
78. FRIEDE M, HENNEICKE VON ZEPELIN HH, FREUDENSTEIN J: Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry (2001) 34(S1):S38-S41.
79. PACHER P, KECSKEMETI V: Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr. Pharm. Des. (2004) 10(20):2463-2475.
80. RAMASUBBU R: Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J. Clin. Psychiatry (2004a) 65(12):1642-1653.
81. RAMASUBBU R: SSRI treatment-associated stroke: causality assessment in two cases. Ann. Pharmacother. (2004b) 38(7-8):1197-1201.
82. DE ABAJO FJ, JICK H, DERBY L, JICK S, SCHMITZ S: Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br. J. Clin. Pharmacol. (2000) 50:43-47.
83. HERGOVICH N, AIGNER M, EICHLER HG, ENTLICHER J, DRUCKER C, JILMA B: Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol. Ther. (2000) 68(4):435-442.
84. SEREBRUANY VL, GURBEL PA, O'CONNOR CM: Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between Depression, coronary events, and mortality benefits of Selective serotonin reuptake inhibitors. Pharmacological Research. (2001) 43:5.
85. BAK S, TSIROPOULOS I, KJÆRSGAARD JO et al.: Selective serotonin reuptake inhibitors and the risk of stroke. A population-based case-control study. Stroke (2002) 33:1465.
86. MEIER CR, SCHLIENGER RG, JICK H: Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br. J. Clin. Pharmacol. (2001) 52:179-184.
87. SAUER WH, BERLIN JA, KIMMEL SE: Selective serotonin reuptake inhibitors and myocardial infarction. Circulation (2001) 104:1894-1898.
88. EVERSON SA, ROBERTS RE, GOLDBERG DE, KAPLAN GA: Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch. Intern. Med. (1998) 158:1133-1138.
89. LARSON SL, OWENS PL, FORD D, EATON W: Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore Epidemiologic Catchment Area Study. Stroke (2001) 32:1979-1983.
90. KRISHNAN KR: Depression as a contributing factor in cerebrovascular disease. Am. Heart. J. (2000) 140:S70-S76.
91. LAYTON D, CLARK DW, PEARCE GL, SHAKIR SA: Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur. J. Clin. Pharmacol. (2001) 57:167-176.
92. KURNE A, ERTUGRUL A, ANIL YAGCIOGLU AE, YAZICI KM: Venous thromboembolism and escitalopram. Gen. Hosp. Psychiatry (2004) 26(6):481-483.
93. GLASSMAN AH, SHAPIRO PA: Depression and the course of coronary artery disease. Am. J. Psychiatry (1998) 155:4-11.
94. MUSSELMAN DL, EVANS DL, NEMEROFF CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry (1998) 55:580-592.
95. LESPERANCE F, JUNEAU M, THEROUX P: Depression and 1-year prognosis in unstable angina. Arch. Intern. Med. (2000) 160:1354-1360.
96. LESPERANCE F, FRASURE-SMITH N, TALAJIC M et al.: Five-year risk of cardiac mortality in relation to initial severity and 1-year changes in depression symptoms after myocardial infarction. Circulation (2002) 105:1049-1053.
97. MUSSELMAN DL, TOMER A, MANATUNGA AK et al.: Exaggerated platelet reactivity in major depression. Am. J. Psychiatry (1996) 153:1313-1317.
98. COHEN HW, GIBSON G, ALDERMAN MH: Excess risk of myocardial infarction in patients treated with antidepressant medication: association with use of tricyclic agents. Am. J. Med. (2000) 108(1):2-8.
99. RASMUSSEN A, LUNDE M, POULSEN DL, SORENSEN K, QVITZAU S, BECH P: A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics (2003) 44:216-221.
100. SEREBRUANY VL, GLASSMAN AH, MALININ AI et al. FOR THE SADHART STUDY GROUP: Platelet/biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after endothelial acute coronary events. The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation (2003) 108:939.
101. GLASSMAN AH, PREUD'HOMME XA: Review of the cardiovascular effects of heterocyclic antidepressants. J. Clin. Psychiatry (1993) 54(Suppl. 2):16-22.
102. ROOSE SP, GLASSMAN AH, GIARDINA EG, JOHNSON LL, WALSH BT, WOODRING S, BIGGER JT: Nortriptyline in depressed patients with left ventricular impairment. JAMA (1986) 256:3253-3257.
103. DAVIES SJ, JACKSON PR, POTOKAR J, NUTT DJ: Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ (2004) 328(7445):939-943.
104. ROOSE SP, LAGHRISSI-THODE F, KENNEDY JS et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA (1998) 279:287-291.
105. FAVA M, ROSENBAUM JF, PAVA JA, MCCARTHY MK, STEINGARD RJ, BOUFFIDES E: Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment. Am. J. Psychiatry (1993) 150(8):1158-1163.
106. BERTHIER ML, KULISEVSKY J: Fluoxetine-induced mania in a patient with post-stroke depression. Br. J. Psychiatry (1993) 163:698-699.
107. KULISEVSKY J, BERTHIER ML: A new case of fluoxetine-induced mania in poststroke depression. Clin. Neuropharmacol. (1997) 20(2):180-181.
108. DE LEÓN OA, FURMAGA KM, KALTSOUNIS J: Mirtazapine-Induced Mania in a Case of Poststroke Depression. J. Neuropsychiatry Clin. Neurosci. (1999) 11:115-116.
109. KIMURA M, TATENO A, ROBINSON RG: Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression merged analysis of nortriptyline trials. Am. J. Geriatr. Psychiatry (2003) 11:320-327.
110. PRESKORN SH: Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J. Psychopharmacol. (1998) 12(3 Suppl. B):S89-S97.
111. ROGER J, CADIEUX MD: Antidepressant drug interactions in the elderly. Understanding the P450 system is half the battle in reducing risks. Postgraduate medicine online (1999) 106:(6).
112. MICHALETS EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy (1998) 18(1):84-112.
113. PALOMÄKI H, KASTE M, BERG A et al.: Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. J. Neurol. Neurosurg. Psychiatry (1999) 66:490-494.
114. NARUSHIMA K, KOSIER JT, ROBINSON RG: Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J. Nerv. Ment. Dis. (2002) 190(5):296-303.
115. JORGE RE, ROBINSON RG, ARNDT S, STARKSTEIN S: Mortality and Poststroke Depression: A Placebo-Controlled Trial of Antidepressants. Am. J. Psychiatry (2003) 160:1823-1829.
116. HEGERL U, MOLLER HJ: Pharmacotherapy of depression in the elderly. Nervenarzt. (2000) 71(1):1-8.
117. JAKOVLJEVIC D, TUOMILEHTO: Use of selective serotonin reuptake inhibitors and the risk of stroke: is there reason for concern? Stroke (2002) 33:1448.
118. MACKAY FJ, DUNN NR, WILTON LV, PEARCE GL, FREEMANTLE SN, MANN RD: A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol. Drug Saf. (1997) 6(4):235-246.
119. SPALLETTA G, GUIDA G, CALTAGIRONE C: Is left stroke a risk-factor for selective serotonin reuptake inhibitor antidepressant treatment resistance? J. Neurol. (2003) 250(4):449-455.
120. GHOGE H, SHARMA S, SONAWALLA S, PARIKH R: Cerebrovascular diseases and depression. Curr. Psychiatry Rep. (2003) 5(3):231-238.
121. SCHUBERT D, BURNS R, PARAS W et al.: Decrease of depression during stroke and amputation rehabilitation. Gen. Hosp. Psychiatry (1992) 14:135-141.
122. COSTA E SILVA JA: From restoration of neuroplasticity to the treatment of depression: clinical experience. Eur. Neuropsychopharmacol. (2004) 14(Suppl. 5):S511-S521.
123. MALBERG JE: Implications of adult hippocampal neurogenesis in antidepressant action. J. Psychiatry Neurosi. (2004) 29(3):196-205.
124. MALBERG JE, SCHECHTER LE: Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharm. Des. (2005) 11(2):145-155.
125. SAIRANEN M, LUCAS M, ERNFORS P, CASTRÉN M, CASTRÉN E: Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. (2005) 25(5):1089-1094.
126. KODAMA M, FUJIOKA T, DUMAN RS: Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry (2004) 56(8):570-580.
127. AICHNER F, ADELWOHRER C, HARING HP: Rehabilitation approaches to stroke. J. Neural. Transm. Suppl. (2002) 63:59-73.